TD Asset Management
GNMX

TD Asset Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

TD Asset Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,352
Closed -$14K – 1465
2018
Q2 		$14K Sell
12,352
-38,041
-75% -$57.8K ﹤0.01% 1410
2018
Q1 		$101K Buy
+50,393
New +$94.6K ﹤0.01% 1332
2016
Q4 		– Sell
-36,500
Closed -$203K – 1415
2016
Q3 		$203K Hold
36,500
– – ﹤0.01% 1369
2016
Q2 		$203K Hold
36,500
– – ﹤0.01% 1321
2016
Q1 		$161K Hold
36,500
– – ﹤0.01% 1325
2015
Q4 		$220K Buy
+36,500
New +$248K ﹤0.01% 1293

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TD Asset Management's GNMX Position: Q3 2018 in Review

TD Asset Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2018, closing a stake of 12,352 shares — an estimated $14K sold.

TD Asset Management first reported a position in GNMX in Q4 2015 and held it in 6 quarters. The position peaked at $220K in Q4 2015. 44 funds tracked by Wall St. Rank hold GNMX as of Q3 2018.

  • TD Asset Management reported no remaining Aevi Genomic Medicine Inc position as of Q3 2018 after selling out during the quarter.
  • TD Asset Management sold 12,352 Aevi Genomic Medicine Inc shares in Q3 2018, an estimated $14K.
  • TD Asset Management first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 6 quarters.
  • TD Asset Management's Aevi Genomic Medicine Inc position peaked at $220K in Q4 2015.
  • 44 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2018.

Based on TD Asset Management's 13F filing for Q3 2018, filed 1 Nov 2018.